Klotho Neurosciences Expands Patent Portfolio in Australia for Klotho Protein Applications and Use

Klotho Neurosciences Expands Patent Portfolio in Australia

Klotho Neurosciences, Inc., listed on NASDAQ under the symbol KLTO, has made a significant stride in its research and development efforts by announcing the acceptance of 18 claims related to a patent application in Australia. This patent highlights the composition and potential applications of the human secreted Klotho protein (s-KL). The Australian patent office, IP Australia, has confirmed that these claims will be granted, marking an important milestone in Klotho's mission to advance therapeutic options for neuromuscular diseases.

The accepted patent claims specifically focus on a human muscle-cell specific promoter that is operatively linked to a nucleic acid sequence encoding the human s-KL protein. This innovative approach is aimed at addressing motor impairments, typically associated with various neuromuscular disorders. Additionally, the claims encompass the use of neuronal cells and induced pluripotent stem cells (iPSC) that contain this promoter and the associated s-KL gene sequence. Other technologies mentioned include advanced cellular delivery systems, such as adeno-associated viral vectors (AAV) and non-viral vectors that target muscle cells or motor neurons specifically.

Dr. Joseph Sinkule, the CEO and founder of Klotho Neurosciences, emphasized the importance of these patent claims for the company's future. According to Dr. Sinkule, this expansion of their patent portfolio is crucial as they strive towards therapeutic replacement or supplementation of Klotho levels in human subjects. As individuals age, the natural decline of Klotho levels in the body is often due to DNA methylation that leads to the silencing of this beneficial gene. Such a reduction impacts neuromuscular tissues critically, increasing the risk of various motor impairments.

The treatment strategies targeted by this patent are designed for individuals suffering from diseases characterized by motor impairment—conditions like amyotrophic lateral sclerosis (ALS), muscular dystrophies, multiple sclerosis (MS), and other critical neuromuscular disorders. The comprehensive nature of these patents indicates Klotho's intention to harness the benefits of s-KL protein significantly, presenting a noteworthy innovation in the therapeutic landscape for hyaluronic supplementation.

The diseases under consideration include not only ALS but also a broad array of neuromuscular conditions such as Charcot-Marie-Tooth disease, Duchenne muscular dystrophy, myasthenia gravis, among others. Each of these diseases poses unique challenges to motor function, and Klotho’s approach could potentially provide new avenues for effective treatment and improved patient outcomes.

Klotho Neurosciences is focusing on developing groundbreaking gene and cell therapies that leverage the anti-aging properties of the Klotho gene. Their aim is to transform the treatment paradigm for neurodegenerative disorders like Alzheimer’s disease, Parkinson’s disease, and age-related neurological conditions. The company's dedication to advancing science in this crucial area holds promise not only for enhancing the quality of life of patients but also for proposing new scientific models of treatment for aging and degeneration-related diseases.

As Klotho continues to push the frontiers of gene therapy, it remains committed to keeping stakeholders informed on the progress of its innovative approaches and ongoing research developments. The company’s statements about its aspirations indicate a forward-looking perspective aimed at navigating the challenges that lie ahead while providing hope to those affected by debilitating motor disorders.

In summary, Klotho Neurosciences' acceptance of its patent claims in Australia presents a pivotal juncture in the biopharmaceutical landscape regarding the treatment of neuromuscular diseases. It signifies not only an expansion of Klotho's intellectual property portfolio but also underscores the potential impact of the Klotho s-KL protein in therapeutic applications, promising advancements in the management of life-altering conditions resulting from motor impairment.